Showing results (481-490 of 7,003) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|June 22, 2021
Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patientsShoko Nakasone, Ayako Suzuki, Hitomi Okazaki, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2021
Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort studyHyung Woo Kim, Ju Sang Kim, Sang Haak Lee
Lung Cancer (Amsterdam, Netherlands)|June 14, 2021
Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysisLihui Liu, Hua Bai, Samuel Seery, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2021
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type diseaseAlexander I Spira, Huakang Tu, Shivani Aggarwal, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2021
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failureT C Lam, K C Tsang, H C Choi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 25, 2021
Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysisMengmeng Zhao, Junqi Wu, Jiajun Deng, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastasesMargriet Kwint, Iris Walraven, Sjaak Burgers, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Timeliness of access to lung cancer diagnosis and treatment: A scoping literature reviewMargo M Jacobsen, Sophie C Silverstein, Michael Quinn, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesisJian Liu, Sung-Nam Cho, San-Pin Wu, et al.
Pageof 701